Intestinal Diseases
Recent clinical, regulatory, research and industry developments relating to this disease.
Implications of gut microbiota-mediated epigenetic modifications in intestinal diseases.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q1 2030.
Clinical MilestonesViewHide
- 2026-07-06ClinicalAN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCERResults expected Q1 2030
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes5
- Gastrointestinal Microbiome2
- Intestinal Diseases2
- Epigenesis, Genetic1
- Intestinal Mucosa1
- Saccharomyces1
Leading journals6
- BMC medicine1
- BMJ (Clinical research ed.)1
- Cell communication and signaling : CCS1
- Experimental & molecular medicine1
- Gut microbes1
- Journal of microbiology and biotechnology1
Leading researchers8
- Bai G1
- Bai JC1
- Catassi C1
- Chelakkot C1
- Chen K1
- Cho JH1
- Ciacci C1
- Cowden JM1
Affiliations (unnormalised)6
- Academy of Chinese Medical Sciences1
- Animal Nutritional Genome and Germplasm Innovation Research Center1
- China-Japan Friendship Hospital1
- College of Animal Science1
- College of Animal Science and Technology1
- Dankook University1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Intestinal diseases are pathological processes affecting any segment of the intestine from the duodenum to the rectum. The supplied literature frames this as a broad category that includes disorders with diverse microbiologic, genetic, and therapeutic aspects, rather than a single disease entity.
The grounding does not support a single cause for intestinal diseases as a whole. It does indicate that some intestinal disorders are associated with gluten ingestion, and that gut microbiota-related and epigenetic factors may contribute to disease development in certain conditions.
The literature emphasizes disruption of intestinal barrier integrity as a key mechanism in intestinal disease. Epithelial tight junction proteins such as occludin, claudins, and zonula occludens help maintain the barrier, and their regulation is influenced by cytokines, small GTPases, post-translational modifications, and microbiota-linked epigenetic changes.
The grounding does not provide general risk factors for intestinal diseases as a category. It does support gluten exposure as relevant to gluten-related intestinal disorders, and altered gut microbiota as a disease-associated factor in some intestinal conditions.
Treatment is described only at a broad modality level. The literature supports probiotics as adjunctive therapy in some intestinal diseases, and also refers to gluten-free diet in gluten-related disorders, but does not establish a single standard treatment for all intestinal diseases.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.